Amongst the different isoforms, KRAS is the most frequently mutated and is especially prevalent in pancreatic, lung, and colorectal cancers.1 Although mutant KRAS was discovered to be a common driver of human cancers in the early 1980s, there were, until very recently, no approved therapeutics against this target. This evidence concerns the gene KRAS and cancer.